SHARON, Pa., May 10 /PRNewswire-FirstCall/ -- NanoLogix, Inc.,
(Pink Sheets: NNLX - News), formerly Infectech, Inc. (Pink Sheets: IFEC), is a
Nanobiotechnology company engaged in the research, development and
commercialization of technologies for the production of bacteria and disease
testing kits, alternative sources of fuel, cancer therapy and remediation of
toxic materials. The Company announced today that its stock symbol has
changed from: OTC: IFEC to OTC: NNLX in accordance with its name change to
NanoLogix's portfolio of 31 patents have yielded a method vital to the
development of nanotechnology products, a method for low cost hydrogen
production, FDA registered products in the medical device industry, a genomic
cancer therapy and methods for cleaning up toxic environments using
bioremediation. According to Lux Research, sales of products that incorporate
nanotechnology are expected to explode over the next five years, from $12.98
billion in 2004 to an estimated $507.74 billion in 2010. The following
validates the value of NanoLogix's broad patent portfolio along with its
current and future product lines.
For a detailed report on NanoLogix please visit:
- FDA Registration of Identikits. NanoLogix receives medical device
exemption from FDA and can begin manufacturing and selling its
biophasic system devices which detect Mycobacterium Tuberculosis (TB),
Mycobacterium avium complex (MAC), Paratuberculosis, Pseudomonas,
Nocardia and up to 34 different bacteria.
- The Indian Journal of Tuberculosis publishes Mahatma Gandhi Institute
of Medical Sciences research for isolation of Mycobacterium Avium
Complex (MAC) using NanoLogix patented paraffin baiting technology.
- Results from initial hydrogen bioreactor study shows 50% hydrogen
- Ohio State University validates NanoLogix patented paraffin baiting
- NanoLogix signs deal with Gannon University to build hydrogen
- NanoLogix in discussions with one of the largest juice companies in
the U.S. to demonstrate feasibility of a pilot scale unit to convert
millions of gallons of wastewater per year into hydrogen gas.
- The Royal Society of Chemistry publishes University of Cincinnati
research for developing Biochips using NanoLogix patented paraffin
- National Science Foundation awards grant to University of Cincinnati
for BioMEMS research using NanoLogix's patented paraffin baiting
- NanoLogix granted patent for nontoxic genomics therapy for cancer.
- Journal of Laboratory Technology for Bioresearch (BioTechniques)
publishes NanoLogix's research on cell death using hydrophobic
About NanoLogix, Inc.
NanoLogix, Inc., http://www.infectech.com , is a technology application
innovator of biogas products and services designed to assist in worldwide
energy independence and reduce pollution from renewable, environmentally-
friendly energy sources. NanoLogix is also engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious human diseases. The Company's patents span the
identification and antibiotic sensitivity testing of 34 disease-producing
bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
(MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes
of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis
in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for
inducing a genetically based induction of "cell suicide" in cells. The
Company's 31 patents can be viewed by visiting
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of 1933
and the Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members of
its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by such
forward-looking statements. Important factors currently known to management
that could cause actual results to differ materially from those in forward-
statements include fluctuation of operating results, the ability to compete
successfully and the ability to complete before-mentioned transactions. The
company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results.
SOURCE NanoLogix, Inc.